[12] Barkstrom, J. (1986), “Recombinant DNA and the Regulation of Biotechnology: Reflections on the Asilomar Conference, Ten Years After”, Akron Law Review, Vol. 19/1, https://ideaexchange.uakron.edu/akronlawreview/vol19/iss1/3.
[21] Bhatt, D. et al. (2022), “A SynBio community comes of age: Political, academical, industrial, and societal developments in the Netherlands”, Biotechnology Notes, Vol. 3, pp. 62-69, https://doi.org/10.1016/j.biotno.2022.07.004.
[37] Bohua, L. et al. (2023), “Ethical framework on risk governance of synthetic biology”, Journal of Biosafety and Biosecurity, Vol. 5/2, pp. 45-56, https://doi.org/10.1016/j.jobb.2023.03.002.
[17] Chadwick, R. and H. Zwart (2013), “From ELSA to responsible research and Promisomics”, Life Sciences, Society and Policy, Vol. 9/1, https://doi.org/10.1186/2195-7819-9-3.
[16] Collins, F. (2001), “Implications of the Human Genome Project for Medical Science”, JAMA, Vol. 285/5, p. 540, https://doi.org/10.1001/jama.285.5.540.
[28] Committee on Gene Drive Research in Non-Human Organisms: Recommendations for Responsible Conduct et al. (2016), Gene Drives on the Horizon, National Academies Press, Washington, D.C., https://doi.org/10.17226/23405.
[15] Damien, P. and V. Guy (2010), The EU Legislation on GMOs - An Overview, https://publications.jrc.ec.europa.eu/repository/handle/JRC57223.
[29] Delaney, N. (2019), “Sheila Jasanoff wants society to reclaim the meaning of life”, Harvard Kennedy School, https://www.hks.harvard.edu/faculty-research/policy-topics/science-technology-data/democracy-science-sheila-jasanoff-wants.
[11] European Commission (2024), Embedding anticipatory governance in Europe’s transitions, https://data.europa.eu/doi/10.2777/3778181.
[13] Grace, K. (2015), The Asilomar Conference: A Case Study in Risk Mitigation, https://intelligence.org/files/TheAsilomarConference.pdf.
[20] Hynek, N. (2025), “Synthetic biology/AI convergence (SynBioAI): security threats in frontier science and regulatory challenges”, AI & SOCIETY, https://doi.org/10.1007/s00146-025-02576-4.
[36] Keiper, F. and A. Atanassova (2025), “International synthetic biology policy developments and implications for global biodiversity goals”, Frontiers in Synthetic Biology, Vol. 3, https://doi.org/10.3389/fsybi.2025.1585337.
[10] Lorenz, P., K. Perset and J. Berryhill (2023), “Initial policy considerations for generative artificial intelligence”, OECD Artificial Intelligence Papers, No. 1, OECD Publishing, Paris, https://doi.org/10.1787/fae2d1e6-en.
[39] OECD (2026), Consensus documents: harmonisation of regulatory oversight in biotechnology, https://www.oecd.org/en/topics/sub-issues/biosafety-novel-food-and-feed-safety/consensus-documents-work-on-harmonisation-of-regulatory-oversight-in-biotechnology.html.
[6] OECD (2025), “Agile mechanisms for responsible technology development”, OECD Science, Technology and Industry Policy Papers, No. 176, OECD Publishing, Paris, https://doi.org/10.1787/2a35358e-en.
[31] OECD (2025), Financing instruments and policy levers to harness biomanufacturing for climate, biodiversity and growth, OECD Publishing, Paris, https://doi.org/10.1787/48bec995-en.
[33] OECD (2025), OECD Regulatory Policy Outlook 2025, OECD Publishing, Paris, https://doi.org/10.1787/56b60e39-en.
[2] OECD (2025), OECD Science, Technology and Innovation Outlook 2025: Driving Change in a Shifting Landscape, OECD Publishing, Paris, https://doi.org/10.1787/5fe57b90-en.
[34] OECD (2025), Regulatory sandbox toolkit: A comprehensive guide for regulators to establish and manage regulatory sandboxes effectively, OECD Publishing, Paris, https://doi.org/10.1787/de36fa62-en.
[3] OECD (2025), “Synthetic biology, AI and automation: A forward-looking technology assessment”, OECD Science, Technology and Industry Policy Papers, No. 187, OECD Publishing, Paris, https://doi.org/10.1787/12158721-en.
[27] OECD (2025), The 2025 EC-OECD Science, Technology and Innovation Policy (STIP) Survey, https://one.oecd.org/document/DSTI/STP(2025)1/en/pdf.
[7] OECD (2024), “Framework for Anticipatory Governance of Emerging Technologies”, OECD Science, Technology and Industry Policy Papers, No. 165, OECD Publishing, Paris, https://doi.org/10.1787/0248ead5-en.
[38] OECD (2021), International Regulatory Co-operation, OECD Best Practice Principles for Regulatory Policy, OECD Publishing, Paris, https://doi.org/10.1787/5b28b589-en.
[32] OECD (2021), Practical guidance on Agile Regulatory Governance to Harness Innovation, https://legalinstruments.oecd.org/public/doc/669/9110a3d9-3bab-48ca-9f1f-4ab6f2201ad9.pdf.
[22] OECD (2020), Regulatory Policy in the Slovak Republic: Towards Future-Proof Regulation, OECD Reviews of Regulatory Reform, OECD Publishing, Paris, https://doi.org/10.1787/ce95a880-en.
[8] OECD (2019), Recommendation of the Council on Responsible Innovation in Neurotechnology, OECD/LEGAL/0457, https://legalinstruments.oecd.org/en/instruments/OECD-LEGAL-0457.
[1] OECD (2014), Emerging Policy Issues in Synthetic Biology, OECD Publishing, Paris, https://doi.org/10.1787/9789264208421-en.
[44] OECD (2007), OECD Best Practice Guidelines for Biological Resource Centres, OECD Publishing, Paris, https://doi.org/10.1787/9789264128767-en.
[43] OECD (n.d.), Recommendation of the Council on Assessing the Sustainability of Bio-Based Products, OECD/LEGAL/0395, https://legalinstruments.oecd.org/en/instruments/OECD-LEGAL-0395.
[42] OECD (n.d.), Recommendation of the Council on Human Biobanks and Genetic Research Databases, OECD/LEGAL/0375, https://legalinstruments.oecd.org/en/instruments/OECD-LEGAL-0375.
[41] OECD (n.d.), Recommendation of the Council on Quality Assurance in Molecular Genetic Testing, OECD/LEGAL/0350, https://legalinstruments.oecd.org/en/instruments/OECD-LEGAL-0350.
[40] OECD (n.d.), Recommendation of the Council on the Licensing of Genetic Inventions, OECD/LEGAL/0342, https://legalinstruments.oecd.org/en/instruments/OECD-LEGAL-0342.
[5] OECD-Hoover Institution (2025), Pathways to Responsible Innovation and Anticipatory Governance of Synthetic Biology.
[18] Office parlementaire d’évaluation des choix scientifiques et technologiques (2012), RAPPORT: LES ENJEUX DE LA BIOLOGIE DE SYNTHÈSE, https://www.assemblee-nationale.fr/13/pdf/rap-off/i4354.pdf.
[25] Patrick, S. (2024), Mitigating Risks of Gene Editing and Synthetic Biology: Global Governance Priorities, CEIP: Carnegie Endowment for International Peace. United States of America., https://coilink.org/20.500.12592/6ba5fug.
[45] Paunov, C. and S. Planes-Satorra (2023), “Engaging citizens in innovation policy: Why, when and how?”, OECD Science, Technology and Industry Policy Papers, No. 149, OECD Publishing, Paris, https://doi.org/10.1787/ba068fa6-en.
[35] Pei, L., M. Garfinkel and M. Schmidt (2022), “Bottlenecks and opportunities for synthetic biology biosafety standards”, Nature Communications, Vol. 13/1, https://doi.org/10.1038/s41467-022-29889-y.
[19] Presidential Commission for the Study of Bioethical Issues (2010), New Directions: The Ethics of Synthetic Biology and Emerging Technologies, https://bioethicsarchive.georgetown.edu/pcsbi/sites/default/files/PCSBI-Synthetic-Biology-Report-12.16.10_0.pdf.
[24] Robinson, D. and D. Doherty (2025), “Strategic intelligence tools for emerging technology governance: A policy primer”, OECD Science, Technology and Industry Working Papers, No. 2025/22, OECD Publishing, Paris, https://doi.org/10.1787/02c05775-en.
[4] Robinson, D. and D. Nadal (2025), “Synthetic biology in focus: Policy issues and opportunities in engineering life”, OECD Science, Technology and Industry Working Papers, No. 2025/03, OECD Publishing, Paris, https://doi.org/10.1787/3e6510cf-en.
[23] Robinson, D., D. Winickoff and L. Kreiling (2023), “Technology assessment for emerging technology: Meeting new demands for strategic intelligence”, OECD Science, Technology and Industry Policy Papers, No. 146, OECD Publishing, Paris, https://doi.org/10.1787/e738fcdf-en.
[9] Sarliève, P. et al. (2025), “A mapping tool for digital regulatory frameworks: Including a pilot on efforts to regulate AI”, OECD Regulatory Policy Working Papers, No. 23, OECD Publishing, Paris, https://doi.org/10.1787/1cdad902-en.
[26] UN Convention on Biological Diversity (2025), Decision 16/21 on Synthetic Biology, adopted by the Conference of the Parties to the Convention on Biological Diversity on 1 November 2024, https://www.cbd.int/doc/decisions/cop-16/cop-16-dec-21-en.pdf.
[14] White House (2015), Modernizing the Regulatory System for Biotechnology Products, https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/biotech_coordinated_framework.pdf.
[30] Winickoff, D. et al. (2021), “Collaborative platforms for emerging technology: Creating convergence spaces”, OECD Science, Technology and Industry Policy Papers, No. 109, OECD Publishing, Paris, https://doi.org/10.1787/ed1e030d-en.